石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

交易中 06-22 11:40:16

6.760

-0.130

-1.89%

最高6.890	最低6.530	成交量3,584万
今开6.890	昨收6.890	日振幅5.23%
总市值778.89亿	流通市值778.89亿	总股本115.22亿
成交额2.38亿	换手率0.31%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":6.76,"timestamp":1782099615827,"preClose":6.89,"halted":0,"volume":35842505,"delay":0,"changeRate":-0.018867924528301872,"floatShares":11522000000,"shares":11522000000,"eps":0.3930797108947525,"marketStatus":"交易中","change":-0.13,"latestTime":"06-22 11:40:16","open":6.89,"high":6.89,"low":6.53,"amount":238322901,"amplitude":0.05225,"askPrice":6.77,"askSize":460000,"bidPrice":6.76,"bidSize":132000,"shortable":3,"etf":0,"ttmEps":0.3308081572832886,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1782100800000},"marketStatusCode":2,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":6.89,"dividendRate":0.02071,"openAndCloseTimeList":[[1782091800000,1782100800000],[1782104400000,1782115200000]],"volumeRatio":1.292541,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":true,"expireDate":1782662400000,"strike":"7.25","timestamp":1782093260110,"price":0.02,"volume":300,"amount":12000,"type":"*"},{"symbol":"CSP.HK","call":true,"expireDate":1785340800000,"strike":"7.25","timestamp":1782092769226,"price":0.14,"volume":225,"amount":63000,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.4937,"impliedVolPercentile":0.3184},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2645092889","title":"国金证券：创新与国际化双轮驱动 石药集团给予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2645092889","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645092889?lang=zh_cn&edition=full","pubTime":"2026-06-21 14:38","pubTimestamp":1782023880,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　国金证券发布研报称，石药集团（01093）为国内综合型头部制药企业，业务版图覆盖制剂（仿制药+创新药）、原料药、功能食品三大板块，经营底盘坚实。研发底蕴深厚，创新转型成效凸显，国际化与商业化落地成果行业领先。该行预计其26-28年归母净利润为79.32/63.28/67.04亿元，对应PE为9.08/11.38/10.74倍。给予公司26年15倍PE估值，目标市值约1190亿元（1379亿港币），给予“买入”评级。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-06-21/doc-inieeaqu1044815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644570451","title":"石药集团(01093)：依达格鲁肽α注射液的第二项上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2644570451","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644570451?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:49","pubTimestamp":1781776161,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本公司附属公司石药集团百克(山东)生物制药股份有限公司开发的依达格鲁肽α注射液(该产品)的第二项上市申请已获中国国家药品监督管理局受理。此前，该产品拟用于超重或肥胖成人的长期体重管理适应症的上市申请，已于2025年10月获国家药监局受理。本次上市申请主要基于两项关键III期临床研究，分别在中国2型糖尿病患者中验证了该产品单药治疗和联合二甲双胍治疗的疗效和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1152091754.HKD","BK1515","LU1813983027.USD","LU0501845795.SGD","LU2039709279.SGD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","IE0008368742.USD","LU1226288253.USD","LU1226287529.USD","SG9999004220.SGD","BK1521","LU1226287792.SGD","LU1226288170.HKD","LU0067412154.USD","LU1008478684.HKD","LU1328277881.USD","LU0314109678.HKD","BK1191","LU1226287875.USD","LU1993786604.SGD","LU0315179316.USD","LU0326950275.SGD","LU0880133367.SGD","HK0000165453.HKD","LU0140636845.USD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1960683339.HKD","LU1807302812.USD","01093","IPOS","LU0072913022.USD","IE00B5MMRT66.SGD","IE0008369823.USD","LU1951186391.HKD","LU1152091168.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644370104","title":"石药集团(01093)：奥曲肽长效注射液(SYHX2008)在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2644370104","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644370104?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:43","pubTimestamp":1781775827,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的奥曲肽长效注射液(该产品)已获得美国食品药品监督管理局批准，可在美国开展临床试验。奥曲肽是治疗肢端肥大症及胃肠胰神经内分泌瘤的一线药物。目前，该产品在中国已进入III期临床研究阶段。临床研究显示，该产品在给药后一周内即可起效，无需先给予短效醋酸奥曲肽注射液，且生化控制率呈现出显著优于已上市奥曲肽微球制剂的趋势。该产品本次获批的临床适应症为肢端肥大症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：奥曲肽长效注射液(SYHX2008)在美国获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226287792.SGD","LU1226288170.HKD","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1226287875.USD","LU0315179316.USD","LU0140636845.USD","LU1152091754.HKD","LU1152091168.USD","LU2039709279.SGD","LU1813983027.USD","HK0000165453.HKD","LU1951186391.HKD","SG9999004220.SGD","BK1191","IE00BZ08YT58.USD","LU0501845795.SGD","LU1008478684.HKD","BK1515","IE00BZ08YS42.EUR","LU0880133367.SGD","LU0326950275.SGD","IE00BZ08YR35.GBP","LU0314109678.HKD","01093","LU1226288253.USD","LU1226287529.USD","BK1521","IE0008369823.USD","LU0072913022.USD","LU1807302812.USD","LU0067412154.USD","LU1960683339.HKD","IE00B543WZ88.USD","LU1993786604.SGD","LU1328277881.USD","IE0008368742.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644577706","title":"国金证券：创新与国际化双轮驱动 予石药集团(01093)“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2644577706","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644577706?lang=zh_cn&edition=full","pubTime":"2026-06-18 14:46","pubTimestamp":1781765162,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，石药集团为国内综合型头部制药企业，业务版图覆盖制剂、原料药、功能食品三大板块，经营底盘坚实。该行预计其26-28年归母净利润为79.32/63.28/67.04亿元，对应PE为9.08/11.38/10.74倍。给予公司26年15倍PE估值，目标市值约1190亿元，给予“买入”评级。风险提示竞争加剧风险、临床试验结果不及预期风险、临床时间及资金成本超预期风险、BD不及预期风险、上市进度不及预期风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745407","title":"石药集团(01093)：受托人根据股份奖励计划购买合共287万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745407","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644745407?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:11","pubTimestamp":1781698273,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，于2026年6月17日，受托人根据2026年股份奖励计划的条款及条件在市场上购买合共287万股公司股份，并为获选参与者的利益以信托方式持有该等股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","LU0314109678.HKD","LU1960683339.HKD","LU0067412154.USD","LU2039709279.SGD","LU0140636845.USD","LU0315179316.USD","LU1813983027.USD","SG9999004220.SGD","LU1328277881.USD","IE00BZ08YS42.EUR","01093","IE00B031HY20.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU0501845795.SGD","LU0072913022.USD","IE0008368742.USD","LU1008478684.HKD","BK1191","LU1152091168.USD","IE00BZ08YR35.GBP","LU1226287529.USD","LU0326950275.SGD","LU1951186391.HKD","BK1521","IE0008369823.USD","IE00B543WZ88.USD","LU1152091754.HKD","LU1226288253.USD","LU1807302812.USD","LU1226288170.HKD","LU1993786604.SGD","LU1226287792.SGD","HK0000165453.HKD","LU1226287875.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643751358","title":"石药集团：缬沙坦马来酸左氨氯地平片上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2643751358","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643751358?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:05","pubTimestamp":1781607900,"startTime":"0","endTime":"0","summary":"6月16日，石药集团（01093）发布公告，公司开发的缬沙坦马来酸左氨氯地平片（SYH9056片）上市许可申请已获国家药监局受理。公告指出，本次申报的适应症为单药治疗不能有效控制的原发性轻中度高血压。该产品为缬沙坦与马来酸左氨氯地平的单片复方制剂（规格：80mg/2.5mg），按照化学药品注册分类2.3类新药申报，具有明显的临床治疗优势。目前，该复方制剂在国内外均未上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606163773213733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1152091754.HKD","BK1515","LU1813983027.USD","LU0501845795.SGD","LU2039709279.SGD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","IE0008368742.USD","LU1226288253.USD","LU1226287529.USD","SG9999004220.SGD","BK1521","LU1226287792.SGD","LU1226288170.HKD","LU0067412154.USD","LU1008478684.HKD","LU1328277881.USD","LU0314109678.HKD","BK1191","LU1226287875.USD","LU1993786604.SGD","LU0315179316.USD","LU0326950275.SGD","LU0880133367.SGD","HK0000165453.HKD","LU0140636845.USD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1960683339.HKD","LU1807302812.USD","01093","IPOS","LU0072913022.USD","IE00B5MMRT66.SGD","IE0008369823.USD","LU1951186391.HKD","LU1152091168.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643756410","title":"石药集团(01093)：受托人根据股份奖励计划购买合共280万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643756410","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643756410?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:40","pubTimestamp":1781606403,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，于2026年6月16日，受托人根据2026年股份奖励计划的条款及条件在市场上购买合共280万股本公司股份，并为获选参与者的利益以信托方式持有该等股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：受托人根据股份奖励计划购买合共280万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0315179316.USD","IE00B5MMRT66.SGD","LU1951186391.HKD","LU1328277881.USD","IE00B031HY20.USD","LU1807302812.USD","IE0008369823.USD","LU1226287529.USD","IE00B543WZ88.USD","LU1152091168.USD","LU0072913022.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","LU0326950275.SGD","SG9999004220.SGD","LU1008478684.HKD","IE0008368742.USD","LU0880133367.SGD","LU0140636845.USD","LU1813983027.USD","LU1993786604.SGD","LU1226287875.USD","LU0501845795.SGD","BK1515","IE00BZ08YR35.GBP","LU1152091754.HKD","BK1521","LU2039709279.SGD","LU1226288170.HKD","01093","BK1191","IE00BZ08YT58.USD","LU1226287792.SGD","LU0314109678.HKD","LU1960683339.HKD","LU0067412154.USD","LU1226288253.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643585817","title":"新诺威(300765.SZ)证券简称变更为“石药创新”","url":"https://stock-news.laohu8.com/highlight/detail?id=2643585817","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643585817?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:20","pubTimestamp":1781601606,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威(300765.SZ)发布公告，自2024年以来，公司依托巨石生物加速向创新型生物医药企业转型，重点布局抗体药物、ADC及mRNA疫苗等前沿技术平台，稳步推进生物药管线研发与产业化，产品覆盖肿瘤、代谢、自身免疫疾病及感染性疾病等多个治疗领域，已形成“研发—生产—商业化”的完整产业链。为进一步强化企业形象与品牌价值，使证券简称与公司主营业务及战略定位相匹配，公司将证券简称由“新诺威”变更为“石药创新”。新证券简称的启用日期为2026年6月17日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","161027","300765","HK0000165453.HKD","LU0326950275.SGD","BK1191","LU1152091754.HKD","BK1515","SG9999004220.SGD","LU0315179316.USD","LU1226288253.USD","LU1807302812.USD","IE0008369823.USD","LU1226287529.USD","LU0067412154.USD","IE00BZ08YS42.EUR","LU1008478684.HKD","BK0226","LU0880133367.SGD","LU0314109678.HKD","LU1152091168.USD","LU1993786604.SGD","IE00B543WZ88.USD","IE00BZ08YT58.USD","LU1951186391.HKD","LU1960683339.HKD","LU1328277881.USD","IE00B031HY20.USD","LU1226287792.SGD","LU1813983027.USD","BK1521","IE0008368742.USD","LU0501845795.SGD","LU1226287875.USD","LU1226288170.HKD","LU0140636845.USD","LU2039709279.SGD","LU0072913022.USD","01093","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152715568","title":"异动解读｜石药集团盘中下跌3.4%，报7.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152715568","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152715568?lang=zh_cn&edition=full","pubTime":"2026-06-16 09:58","pubTimestamp":1781575098,"startTime":"0","endTime":"0","summary":"6月16日，石药集团盘中下跌3.4%，报7.1港元/股，成交额8263.06万港元。石药集团所在的制药行业中，个股中，中国生物制药跌2.93%，翰森制药跌0.67%，恒瑞医药涨0.83%，和黄医药跌2.23%，海西新药涨7.23%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643086032","title":"石药集团(01093)：注射用紫杉醇(白蛋白结合型)(II)获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2643086032","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643086032?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:35","pubTimestamp":1781523346,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的注射用紫杉醇已获得中国国家药品监督管理局批准上市，为全球首个速溶白蛋白结合型紫杉醇制剂。一项多中心、随机、双盲的关键Ⅲ期临床研究结果显示，该产品在乳腺癌患者中较注射用紫杉醇具有更显著的疗效获益：独立评审委员会及研究者评估的客观缓解率组间比值分别为1.38 和1.33 ，均达到优效标准;疾病进展或死亡风险降低27%;死亡风险降低33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","LU1226288170.HKD","SG9999004220.SGD","BK1515","LU1993786604.SGD","01093","LU0315179316.USD","IE00BZ08YT58.USD","LU0326950275.SGD","LU1813983027.USD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU1226287792.SGD","BK1521","LU0880133367.SGD","LU2039709279.SGD","HK0000165453.HKD","LU1226288253.USD","LU1152091168.USD","LU0072913022.USD","LU0067412154.USD","LU1951186391.HKD","IE0008368742.USD","IE00B543WZ88.USD","LU1226287875.USD","LU0314109678.HKD","LU0501845795.SGD","LU1960683339.HKD","LU1807302812.USD","IE0008369823.USD","LU1328277881.USD","IPOS","BK1191","LU1152091754.HKD","LU1226287529.USD","LU0140636845.USD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03329","02096","LU1960683339.HKD","LU0348827113.USD","01951","LU1226287875.USD","09996","LU2399975544.HKD","06996","09926","LU2097828631.EUR","02273","06821","01530","02162","LU1880383366.USD","06990","HK0000320264.USD","LU1242518857.USD","LU0140636845.USD","02596","01952","LU0051755006.USD","LU1688375341.USD","01276","01177","01801","03759","09966","LU0181495838.USD","BK1576","HK0000306685.HKD","LU0502904849.HKD","BK1191","SG9999002562.SGD","02269","LU0456827905.SGD","02268","03692","06078","01093","LU0737861772.HKD","LU0320764599.SGD","IE00B0JY6N72.USD","LU0819121731.USD","01548","IE00BZ08YR35.GBP","06160","LU3063872942.SGD","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111872950","title":"异动解读｜石药集团盘中上涨3.04%，司美格鲁肽月制剂获FDA临床批准持续提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1111872950","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111872950?lang=zh_cn&edition=full","pubTime":"2026-06-15 09:58","pubTimestamp":1781488706,"startTime":"0","endTime":"0","summary":"6月15日，石药集团盘中上涨3.04%，报7.42港元/股，成交额1.4亿港元。消息面上，公司近期公告其自主研发的GLP-1受体激动剂司美格鲁肽长效注射液已获美国FDA批准开展临床试验，该产品为每月给药一次的长效制剂，相较已上市产品每周一次的给药方式具有明显临床优势，系国产药企首次将月制剂改良型新药推入美国临床阶段，积极情绪延续。此外，公司根据股份奖励计划在公开市场购入550万股股份，制药板块今日整体走强亦形成支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642744524","title":"智通港股早知道 | 美国5月CPI同比上涨4.2% 工信部：加强高端光电芯片和器件研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2642744524","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642744524?lang=zh_cn&edition=full","pubTime":"2026-06-11 07:42","pubTimestamp":1781134977,"startTime":"0","endTime":"0","summary":"热门中概股多数下跌，纳斯达克中国金龙指数跌0.28%。美国5月CPI同比上涨4.2%美国劳工部10日发布的数据显示，受能源价格上涨推动，美国5月消费者价格指数同比上涨4.2%，创2023年5月以来新高。其他在产锂精矿工厂的运营不受此次事件影响。报道称，蚂蚁、General Atlantic和Silver Lake代表均不予置评。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B031HY20.USD","LU2750360641.GBP","LU0053666078.USD","SG9999015986.USD","LU0256863902.USD","IE00BKDWB100.SGD","LU2417539215.USD","GB00BDT5M118.USD","LU1623119135.USD","LU2347655073.USD","BK4534","LU0965508806.USD","LU2237443895.HKD","IE0034235188.USD","LU0289961442.SGD","IE00BJJMRX11.SGD","IE00BMCWC346.EUR","00354","BK0155","LU1037948541.HKD","IE0008369823.USD","LU0187121727.USD","LU2462157665.USD","LU2247934214.USD","LU2237443622.USD","LU0476273544.USD","BK1518","LU0353189763.USD","LU0444971666.USD","LU0957791311.USD","LU2764263203.CNY","LU0203347892.USD","LU0133085943.USD","IE00B19Z3581.USD","LU2028103732.USD","LU0143551892.USD","IE00BK4W5L77.USD","LU2065170008.USD","LU0795875169.SGD","LU1069344957.HKD","LU0124676726.USD","LU0345770993.USD","LU1066051225.USD","LU2430703251.USD","LU2471134523.USD","LU0170899867.USD","LU2168564065.EUR","LU2279689827.SGD","IE00BN29S564.USD","LU2860962120.EUR","LU0784383803.USD","LU0501845795.SGD","LU2089284900.SGD","BK4585","AVL","LU2420271590.USD","LU0949170426.SGD","LU0345768153.USD","LU0348723411.USD","LU1807302812.USD","LU0786609619.USD","LU2125909247.SGD","LU0943347566.SGD","LU0234572021.USD","LU2237443549.SGD","BK1205","LU2322448791.USD","AVS","BK0077","LU0788109477.HKD","IE0004445239.USD","AVGU","IE0002270589.USD","IE00BGHQDM52.EUR","LU0061474960.USD","LU2242650005.HKD","LU0082616367.USD","LU2236285917.USD","LU2637965513.SGD","LU1400636657.SGD","IE00BVYPNQ40.USD","LU1868837136.USD","LU0140636845.USD","LU1328277881.USD","LU0276348264.USD","LU0820562030.AUD","LU2360032135.SGD","LU1400636574.HKD","SG9999015945.SGD","LU1720051017.SGD","LU0949170772.SGD","BK1574","LU1670756490.USD","LU2237957902.USD","LU0251132253.USD","IE00B5MMRT66.SGD","AVGG","BK1191","LU0320765646.SGD","LU0274383776.USD","LU2125154778.USD","LU2471134952.CNY","LU0096364046.USD","LU0683600562.USD","LU0784384876.USD","LU1989764748.USD","BK4515","LU2237443465.HKD","LU0061474705.USD","LU0203201768.USD","LU0345770308.USD","BK4579","CHSTY","LU0957808578.USD","LU2065171402.SGD","LU0880133367.SGD","HK0000914660.USD","IE00BJLML261.HKD","LU2092937221.SGD","LU0158827781.USD","BK4575","LU1914381329.SGD","00658","LU0057025933.USD","LU1244550494.USD","LU1035775433.USD","LU1868836757.USD","LU2106854487.HKD","LU0784385840.USD","BK4581","SG9999015978.USD","LU0203345920.USD","LU2237443978.SGD","LU1804176565.USD","LU0070217475.USD","LU0315179316.USD","LU0640476718.USD","AVGX","BK0182","IE00B3PB1722.GBP","LU1670710588.SGD","LU1935043536.SGD","LU0210533765.USD","LU2357627491.SGD","LU0417517546.SGD","SG9999004220.SGD","IE0034235303.USD","LU0738911758.USD","LU2168564222.USD","LU2999663052.SGD","LU1852331112.SGD","LU0553294199.USD","LU1923623000.USD","LU1153585028.USD","SGXZ99366536.SGD","LU0820561818.USD","LU1226288253.USD","BK0196","LU1261432733.SGD","LU0979878070.USD","IE00BJTD4V19.USD","IE00B4JS1V06.HKD","BK4543","LU1814569148.SGD","LU0127658192.USD","BK0197","IE00B7SZLL34.SGD","BK4533","LU1127390331.HKD","BK4588","LU1935042991.SGD","LU2505996509.AUD","QCMD","LU2244417387.USD","IE00B19Z9P08.USD","IE00BWXC8680.SGD","LU0061475181.USD","LU1951200564.SGD","LU0868494617.USD","LU0006306889.USD","LU1934455277.USD","LU1084165304.USD","LU0859254822.USD","01763","LU1119994496.HKD","LU2746668974.SGD","IE00B1BXHZ80.USD","SGXZ51526630.SGD","LU0316494557.USD","IE00BYV24P56.USD","LU1323610961.USD","IE00B775H168.HKD","LU2471134796.USD","IE00BJTD4N35.SGD","BK4598","BK4141","LU0215105999.USD","LU2264538146.SGD","LU2355687059.USD","LU2322448957.HKD","LU0203202063.USD","LU0511384066.AUD","LU1923622614.USD","LU0154236417.USD","LU2041044095.USD","LU1989764664.SGD","LU2065169927.USD","LU1718418525.SGD","LU2133065610.SGD","LU0912757837.SGD","LU0444973449.USD","LU0642271901.SGD","BK4532","LU2458330169.SGD","BK1179","LU2111349929.HKD","IE00B775SV38.USD","LU0011850046.USD","LU0965509010.AUD","LU1823568750.SGD","SGXZ81514606.USD","IE00BQXX3D17.EUR","LU1226288170.HKD","LU1815333072.USD","LU0210528500.USD","LU0198837287.USD","LU2237443382.USD","LU1242518931.SGD","LU1366333091.USD","LU0320765059.SGD","LU0861579265.USD","LU1642822529.SGD","IE00BJJMRY28.SGD","IE00BMPRXR70.SGD","LU1691799644.USD","LU1064131342.USD","LU2168563687.JPY","BK1521","IE00BZ08YS42.EUR","LU2487616109.SGD","LU2756315664.SGD","LU0889565833.HKD","LU2213496289.HKD","IE00BBT3K403.USD","LU1720051108.HKD","LU2458330243.SGD","HK0000914686.HKD","LU1244550221.USD","LU2265009873.SGD","LU0158827948.USD","LU1267930730.SGD","QCML","IE00BQXX3F31.USD","LU0964807845.USD","LU1301847155.USD","LU0868494708.USD","LU1992135472.HKD","IE00BVYPNW00.USD","AVGO","BK1515","BK0233","LU1008478684.HKD","LU1935042488.USD","LU0965509101.SGD","LU2298321311.HKD","LU2361044865.SGD","LU0345768740.USD","IE00BLSP4239.USD","00031","LU1974910355.USD","LU0157215616.USD","LU0079474960.USD","SG9999004303.SGD","LU1989772923.USD","SG9999001424.SGD","LU1551013425.SGD","LU2023251221.USD","HK0000165453.HKD","IE0001KFT4U8.USD","IE00B3S45H60.SGD","LU0081259029.USD","LU2210149790.SGD","LU0225283273.USD","LU0354030511.USD","LU0726765562.USD","BK4605","LU0792757196.USD","LU0787776722.HKD","LU0353189680.USD","LU1226287529.USD","LU0289739343.SGD","BK4566","LU0719512351.SGD","LU2347655156.SGD","SG9999011175.SGD","LU2764262908.HKD","IE00BZ9MQY76.HKD","LU0256863811.USD","BK4612","LU0345769631.USD","BK0028","LU0466842654.USD","LU1951186391.HKD","IE00BFSS7M15.SGD","LU1400636491.USD","IE00B42XCP33.USD","LU2023250504.SGD","LU1935042215.USD","LU0823434583.USD","SG9999002232.USD","IE00B894F039.SGD","01093","SGXZ23171101.USD","LU0308772762.SGD","LU1670711123.USD","LU0067412154.USD","LU1003077747.HKD","LU1993786604.SGD","IE00BQXX3C00.GBP","LU2089985449.USD","LU1674673428.USD","BK4561","LU0238689110.USD","IE00BMPRXN33.USD","LU1670710661.SGD","LU2360106780.USD","IE00B7KXQ091.USD","IE00BVYPNP33.GBP","HK0000532082.HKD","LU1868837300.USD","LU2048586759.USD","LU0354030438.USD","LU2543165471.USD","LU2357305700.SGD","LU1267930813.SGD","LU0109391861.USD","LU1815336760.USD","LU2360108059.USD","LU2461242641.AUD","LU1242518857.USD","MUD","LU0174119429.USD","LU2430703178.SGD","LU1732799900.SGD","LU1037948897.HKD","LU0942090050.USD","LU1670711040.USD","LU1917777945.USD","LU0210536198.USD","IE00BVYPNV92.GBP","BK1586","LU1202635105.USD","LU1989772840.SGD","LU1813983027.USD","LU2125909593.SGD","BK4604","BK1178","LU0048584097.USD","LU2211814178.USD","09966","SG9999015952.SGD","LU0689472784.USD","LU1935043023.USD","LU2271345857.HKD","LU1988902786.USD","AVGW","LU0234570918.USD","LU2039709279.SGD","LU0096362180.USD","SG9999003800.SGD","LU1645745479.HKD","LU1674673691.USD","LU0795875086.SGD","LU2720916845.USD","LU2063271972.USD","MU","IE00BSNM7G36.USD","IE00BZ08YT58.USD","LU2473716301.USD","QCOM","BK4551","IE00BLSP4452.SGD","LU1670627923.USD","BK4512","LU1732800096.USD","LU2471134879.HKD","01277","LU2746668461.USD","LU2083900584.USD","LU0689626769.HKD","LU1960683339.HKD","LU0820561909.HKD","LU1951198990.SGD","LU1934455194.USD","LU2250418816.HKD","LU2896262040.SGD","IE00BZ08YR35.GBP","LU0072462426.USD","LU0545039389.USD","BK4527","LU2089283258.USD","LU0661504455.SGD","LU1366192091.USD","LU1868836914.USD","LU0823434740.USD","LU0106261372.USD","SG9999002224.SGD","LU0672654240.SGD","LU1934455863.HKD","LU1226287792.SGD","002466","LU2462591350.SGD","LU0323591593.USD","BK4554","LU2237438978.USD","BK1161","LU0080751232.USD","LU2954938101.SGD","BK1589","IE0004445015.USD","LU1226287875.USD","LU1712237335.SGD","LU2237957811.SGD","LU2168564149.EUR","LU1280957306.USD","MUU","LU2764263039.SGD","SG9999001440.SGD","LU1046421795.USD","LU2023250330.USD","LU1496350502.SGD","BK4573","LU2168564495.EUR","IE00B1XK9C88.USD","IE0008368742.USD","LU1629891620.HKD","LU0314104364.USD","LU1551013342.USD","IE00BKVL7J92.USD","LU0708995401.HKD","LU2602419157.SGD","LU1803068979.SGD","LU1868836591.USD","IE00B543WZ88.USD","LU2361044949.HKD","IE00BZ1G4Q59.USD","LU0211328371.USD","LU2211815571.USD","LU2462591277.SGD","IE00BMPRXQ63.HKD","BK1526","LU0965509283.SGD","IE0005OL40V9.USD","LU1670628061.USD","LU0072913022.USD","LU2272731782.SGD","IE00BGHQF631.EUR","LU1152091168.USD","LU0784385170.HKD","SG9999000418.SGD","IE00B5949003.HKD","LU2054465674.USD","LU2272731865.HKD","LU2931357623.SGD","LU1244550577.SGD","BK1155","LU1066051811.HKD","LU1066053197.SGD","09696","LU2087625088.SGD","IE00BKPKM429.USD","LU1145028129.USD","LU2286300806.USD","LU2108987350.USD","IE00BN8TJ469.HKD","LU0472753341.HKD","LU1267930490.SGD","IE00B19Z3B42.SGD","QCMU","IE00B19Z9Z06.USD","LU0889566641.SGD","LU0097036916.USD","LU0985320562.USD","LU2592432038.USD","LU2242649171.HKD","IE00BDGV0183.EUR","MULL","LU2433249047.HKD","LU2403377893.USD","LU2095319765.USD","LU0211327993.USD","LU1232071149.USD","LU2272731600.USD","LU2505996681.GBP","BK1222","LU0345769128.USD","LU1066051498.USD","LU2361045086.USD","LU2750360997.AUD","LU2456880835.USD","LU0326950275.SGD","LU1162221912.USD","IE00BFSS8Q28.SGD","LU1316542783.SGD","LU2210150020.SGD","LU2756315318.SGD","LU2463028550.USD","LU0069063385.USD","LU1992135399.USD","LU0266013472.USD","LU0109392836.USD","BK0183","LU1778281490.HKD","LU0314109678.HKD","BK4553","LU0310799852.SGD","LU2065171311.SGD","LU2023250843.SGD","LU2430703095.HKD","LU0056508442.USD","IE00BK4W5M84.HKD","IE0009356076.USD","LU1152091754.HKD","LU1803068623.USD","BK1546","LU1548497426.USD","LU2125154935.USD","LU0724617625.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642468104","title":"港股异动 | 石药集团(01093)盘中涨超4% 司美格鲁肽长效注射液(SYH9017)获FDA批准临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2642468104","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642468104?lang=zh_cn&edition=full","pubTime":"2026-06-10 15:50","pubTimestamp":1781077840,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药集团盘中涨超4%，截至发稿，涨3.57%，报7.25港元，成交额7.14亿港元。消息面上，石药集团公告，集团开发的GLP-1受体激动剂司美格鲁肽长效注射液已获美国食品药品监督管理局批准，可在美国开展临床试验。据悉，该产品是本集团在GLP-1领域布局的首个每月给药一次的长效制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","BK4585","HK0000165453.HKD","LU0326950275.SGD","BK1191","LU1152091754.HKD","LABU","BK4588","BK1515","SG9999004220.SGD","LU0315179316.USD","LU1226288253.USD","LU1807302812.USD","IE0008369823.USD","LU1226287529.USD","LU0067412154.USD","IE00BZ08YS42.EUR","LU1008478684.HKD","LU0880133367.SGD","LU1993786604.SGD","LU0314109678.HKD","LU1152091168.USD","IE00B543WZ88.USD","IE00BZ08YT58.USD","LU1951186391.HKD","LU1960683339.HKD","LU1328277881.USD","IE00B031HY20.USD","LU1226287792.SGD","LU1813983027.USD","BK1521","IE0008368742.USD","LU0501845795.SGD","LU1226287875.USD","LU1226288170.HKD","LU0140636845.USD","LU2039709279.SGD","LU0072913022.USD","VXUS","01093","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180035137","title":"异动解读｜石药集团盘中上涨3.29%，司美格鲁肽月制剂获FDA临床试验批准提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1180035137","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180035137?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:18","pubTimestamp":1781061492,"startTime":"0","endTime":"0","summary":"6月10日，石药集团盘中上涨3.29%，报7.23港元/股，成交额2.87亿港元，逆势跑赢制药板块。消息面上，公司6月8日公告其自主研发的GLP-1受体激动剂司美格鲁肽长效注射液已获美国FDA批准开展临床试验，适应症为成人超重或肥胖患者的体重管理。该产品为每月给药一次的长效制剂，相较已上市司美格鲁肽每周一次的给药方式具有明显临床优势，系国产药企首次将月制剂改良型新药推入美国临床阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642441408","title":"新股消息 | 石药创新(300765.SZ)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2642441408","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642441408?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:18","pubTimestamp":1781061490,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药创新制药股份有限公司于2025年12月10日所递交的港股招股书满6个月，于2026年6月10日失效，递表时中信证券为其独家保荐人。目前已在抗体药物、抗体偶联药物及mRNA疫苗领域累积了深厚技术实力。截至最后实际可行日期，该公司拥有15个处于临床或后期开发阶段的在研药物，其中包括9款ADC在研药物和1款mRNA疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","LU1226288170.HKD","LU0880133367.SGD","VXUS","IE00BZ08YS42.EUR","LU1226288253.USD","LU1226287875.USD","IE0008369823.USD","LU1328277881.USD","LU1807302812.USD","LU1226287792.SGD","LU1008478684.HKD","IE00B543WZ88.USD","300765","LU0140636845.USD","LU1993786604.SGD","IE0008368742.USD","BK4588","BK4585","IE00BZ08YR35.GBP","LU1152091754.HKD","LU1152091168.USD","LU0314109678.HKD","BK1515","LU1226287529.USD","IE00B5MMRT66.SGD","LU0072913022.USD","LU1960683339.HKD","LU0501845795.SGD","IE00BZ08YT58.USD","LU0315179316.USD","LU2039709279.SGD","BK0226","LU1951186391.HKD","LU0067412154.USD","01093","SG9999004220.SGD","LU1813983027.USD","HK0000165453.HKD","LU0326950275.SGD","BK1521","BK1191","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642863452","title":"石药GLP-1月制剂闯关FDA：加速走出低价仿制红海，国产减肥药卷到新维度","url":"https://stock-news.laohu8.com/highlight/detail?id=2642863452","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642863452?lang=zh_cn&edition=full","pubTime":"2026-06-09 14:13","pubTimestamp":1780985622,"startTime":"0","endTime":"0","summary":"在仿制端，司美格鲁肽类似药的大规模放量将迅速拉低整体GLP-1针剂的价格门槛，惠及广大患者的同时加速尾部药企出清。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1780984647666134242","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4144","BK1515","LU0314109678.HKD","LU1960683339.HKD","LU0067412154.USD","BK4585","LU2039709279.SGD","LU0140636845.USD","LU0315179316.USD","LU1813983027.USD","SG9999004220.SGD","LU1328277881.USD","IE00BZ08YS42.EUR","01093","IE00B031HY20.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU0501845795.SGD","LU0072913022.USD","IE0008368742.USD","LU1008478684.HKD","BK1191","LU1152091168.USD","GLP","IE00BZ08YR35.GBP","LABU","BK4588","LU0326950275.SGD","LU1226287529.USD","LU1951186391.HKD","BK1521","IE0008369823.USD","IE00B543WZ88.USD","LU1152091754.HKD","LU1226288253.USD","LU1807302812.USD","LU1226288170.HKD","LU1993786604.SGD","LU1226287792.SGD","HK0000165453.HKD","LU1226287875.USD","BK4590","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641484142","title":"石药集团：根据2026年股份奖励计划购买550.00万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2641484142","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641484142?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:34","pubTimestamp":1780922040,"startTime":"0","endTime":"0","summary":"南财智讯6月8日电，石药集团（01093.HK）发布自愿公告，于2026年6月8日，受托人根据2026年股份奖励计划在公开市场上购买合共550.00万股公司股份，每股平均价格约7.07港元，总代价约3889.50万港元。此次购买的股份占公司已发行股份总数约0.05%。截至公告日期，受托人共持有1930.00万股股份，占已发行股份总数约0.17%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606083763838612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","LU0314109678.HKD","LU1960683339.HKD","LU0067412154.USD","LU2039709279.SGD","LU0140636845.USD","LU0315179316.USD","LU1813983027.USD","SG9999004220.SGD","LU1328277881.USD","IE00BZ08YS42.EUR","01093","IE00B031HY20.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU0501845795.SGD","LU0072913022.USD","IE0008368742.USD","LU1008478684.HKD","BK1191","LU1152091168.USD","IE00BZ08YR35.GBP","LU1226287529.USD","LU0326950275.SGD","LU1951186391.HKD","BK1521","IE0008369823.USD","IE00B543WZ88.USD","LU1152091754.HKD","LU1226288253.USD","LU1807302812.USD","LU1226288170.HKD","LU1993786604.SGD","LU1226287792.SGD","HK0000165453.HKD","LU1226287875.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641813814","title":"石药集团(01093)：司美格鲁肽长效注射液(SYH 9017) 在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2641813814","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641813814?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:49","pubTimestamp":1780919397,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的GLP-1受体激动剂司美格鲁肽长效注射液已获美国食品药品监督管理局批准，可在美国开展临床试验。相较已上市的司美格鲁肽注射液每周一次的给药方式，该产品预期可延长至每月给药一次，大幅提高患者用药的依从性，具有明显临床优势。该产品是集团在GLP-1领域布局的首个每月给药一次的长效制剂，此次美国临床试验的获批，为未来更多创新产品的开发奠定了坚实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：司美格鲁肽长效注射液(SYH 9017) 在美国获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","LU1226288170.HKD","SG9999004220.SGD","BK1515","LU1993786604.SGD","01093","LU0315179316.USD","IE00BZ08YT58.USD","LU0326950275.SGD","LU1813983027.USD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU1226287792.SGD","BK1521","LU0880133367.SGD","LU2039709279.SGD","HK0000165453.HKD","LU1226288253.USD","LU1152091168.USD","LU0072913022.USD","LU0067412154.USD","LU1951186391.HKD","IE0008368742.USD","IE00B543WZ88.USD","LU1226287875.USD","LU0314109678.HKD","LU0501845795.SGD","LU1960683339.HKD","LU1807302812.USD","IE0008369823.USD","LU1328277881.USD","BK1191","LU1152091754.HKD","LU1226287529.USD","LU0140636845.USD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641818794","title":"石药集团(01093)授出合共135万股受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2641818794","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641818794?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:46","pubTimestamp":1780919192,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，于2026年6月8日，本公司根据2018年股份奖励计划向本集团2名获选参与者(获授人)无偿授出合共135万股受限制股份(奖励股份)，惟须待获授人接纳及达成若干归属条件与表现目标后，方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0326950275.SGD","LU2039709279.SGD","IE00BZ08YR35.GBP","LU0880133367.SGD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU0072913022.USD","LU1226287875.USD","LU1951186391.HKD","LU1960683339.HKD","LU1226288253.USD","LU0314109678.HKD","IE00B031HY20.USD","LU0067412154.USD","LU1226287792.SGD","IE0008369823.USD","BK1191","BK1515","SG9999004220.SGD","LU1008478684.HKD","01093","LU1813983027.USD","HK0000165453.HKD","BK1521","LU0501845795.SGD","LU1993786604.SGD","LU0315179316.USD","LU1226288170.HKD","IE0008368742.USD","LU1226287529.USD","LU1152091168.USD","LU1328277881.USD","LU1807302812.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU1152091754.HKD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0444},{"period":"1month","weight":-0.0752},{"period":"3month","weight":-0.217},{"period":"6month","weight":-0.1598},{"period":"1year","weight":-0.1395},{"period":"ytd","weight":-0.1827}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.0535},{"period":"6month","weight":-0.0687},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门：成药部门、抗生素（中间体及原料药）部门、维生素C（原料药）部门及咖啡因及其他（原料药）部门，分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094687},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017323},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057765},{"month":5,"riseRate":0.59375,"avgChangeRate":0.04257},{"month":6,"riseRate":0.3125,"avgChangeRate":0.000981},{"month":7,"riseRate":0.375,"avgChangeRate":0.009082},{"month":8,"riseRate":0.4375,"avgChangeRate":0.010009},{"month":9,"riseRate":0.5,"avgChangeRate":0.000153},{"month":10,"riseRate":0.5625,"avgChangeRate":0.010484},{"month":11,"riseRate":0.46875,"avgChangeRate":0.00638},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013271}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}